Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Share-based Compensation (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Share-based Compensation for 8 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 6.3% to $2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.3 million, a 22.79% decrease, with the full-year FY2024 number at $10.8 million, down 9.33% from a year prior.
  • Share-based Compensation was $2.7 million for Q3 2025 at Whitehawk Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.6 million in Q1 2024 to a low of $36000.0 in Q1 2021.
  • A 5-year average of $2.3 million and a median of $2.7 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 89.01% in 2021, then surged 5630.77% in 2022.
  • Whitehawk Therapeutics' Share-based Compensation stood at $1.4 million in 2021, then soared by 107.52% to $2.9 million in 2022, then increased by 8.4% to $3.1 million in 2023, then crashed by 40.41% to $1.9 million in 2024, then soared by 46.6% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Share-based Compensation are $2.7 million (Q3 2025), $3.1 million (Q2 2025), and $1.7 million (Q1 2025).